Feb. 22 (Bloomberg) -- Israel’s TA-25 index declined for the first time in four days, sliding 0.2 percent to 1,117.98 at the close in Tel Aviv. Investors traded about 1.1 billion shekels ($292.5 million) of shares and convertible securities, according to bourse data.
The following stocks rose or fell today. Symbols are in parentheses.
Camtek Ltd. (CAMT IT) tumbled 8.7 percent, the most since August 10, to 8.662 shekels, bringing the company’s two-day drop to 12 percent. The maker of optical-inspection systems reported a fourth-quarter loss yesterday.
D-Pharm Ltd. (DPRM IT) rallied 30 percent, the biggest jump since Bloomberg started tracking the shares in August 2009, to 1.25 shekels. The biopharmaceutical company said the loss for the year narrowed to 45.7 million shekels ($12 million) compared with a loss of 47.3 million in 2010 and that it is considering the acquisition of Thrombotech Ltd. which is developing a peptide that improves the efficiency of stroke medication.
Can Fite Biopharma Ltd. (CFBI IT) advanced 3.4 percent to 0.46 shekel. The biopharmaceutical company said its CF102 drug for the treatment of primary liver cancer received orphan drug status from the U.S. Food and Drug Administration. Ophthalix Inc., a unit, received a patent in China.
Habas H.Z. Investments (1960) Ltd. (HBS IT) rose 3 percent, the most since Dec. 14, to 5.297 shekels. The investment and holding company said it received early commitments from institutions for about 54.5 million shekels in a tender to extend its series four bonds.
Partner Communications Co. (PTNR IT) slumped 4.4 percent, the biggest decline since Jan. 25, to 30.11 shekels. Israel’s second-largest mobile-phone company postponed final results until the end of March and forecast a drop in fourth-quarter profit. Cellcom Israel Ltd. (CEL IT), the country’s biggest mobile-phone company, fell 3 percent to 52.77 shekels, the lowest close on record.
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at firstname.lastname@example.org
To contact the editor responsible for this story: Claudia Maedler at email@example.com